Caverion Signs Agreement with Novo Nordisk to Deliver New Insulin Production Facility in Denmark

Caverion delivers a Large Project for Novo Nordisk’s new insulin production facility in Hillerød, Denmark

Caverion has signed an agreement with global healthcare company, Novo Nordisk A/S on the delivery of a Large Project for a new pharmaceutical filling factory in Hillerød, Denmark. Caverion is responsible for Project Execution within the discipline of Ventilation. The contract has a volume of approximately EUR 5.4 million.

The facility will produce medicines for the treatment of diabetes and obesity.

“We are very excited to be part of a major new facility. In addition, our role is crucial for ensuring the production capacity of a life-saving medicine. Our previous experience in the pharmaceutical industry is important as this project is demanding and we need to meet very high standards,” says Knut Gaaserud, Executive Vice President & CEO division Denmark-Norway of Caverion.

The factory constitutes an area of 35,000 m2. The facility is expected to be operational in 2019 and it will create 450 new production and engineering jobs in Hillerød where Novo Nordisk already employs 1,900 people.

The project started in June 2016 and ends in February 2017. The builder is Novo Nordisk A/S. The project belongs to Caverion’s real estate users client segment.

Source: http://www.caverion.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit